<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826864</url>
  </required_header>
  <id_info>
    <org_study_id>11-002177</org_study_id>
    <secondary_id>NCI-2013-00645</secondary_id>
    <secondary_id>11-002177</secondary_id>
    <nct_id>NCT01826864</nct_id>
  </id_info>
  <brief_title>Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma</brief_title>
  <official_title>Randomized Phase III Trial to Compare the Immunodulatory Effects of Leukine vs. Saline for Early-stage Melanoma Patients Undergoing Sentinel Lymph Node Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see
      how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating
      patients with melanoma. Biological therapies, such as sargramostim, may stimulate the immune
      system in different ways and stop cancer cells from growing. It is not yet known whether
      sargramostim is more effective than hypertonic saline in treating patients with stage IB-II
      melanoma undergoing sentinel lymph node biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if the alterations in morphology and phenotype to the sentinel lymph nodes
      are reversible.

      II. To determine if the restoration of the morphology or phenotype of sentinel lymph nodes
      results in diminished regional tumor burden.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive sargramostim subcutaneously (SC) 3-5 days prior to undergoing
      sentinel lymph node biopsy.

      ARM II: Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph
      node biopsy.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled
  </why_stopped>
  <start_date type="Actual">August 5, 2011</start_date>
  <completion_date type="Actual">August 8, 2017</completion_date>
  <primary_completion_date type="Actual">August 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of alterations in the SN</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>A series of analysis of variance (ANOVA) models will be employed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with positive SN in each group</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The primary analysis will be a two group continuity corrected Chi-squared test. A logistic regression analysis will also be run.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>A two sample t-test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>A two sample t-test will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage IB Melanoma</condition>
  <condition>Stage IIA Melanoma</condition>
  <condition>Stage IIB Melanoma</condition>
  <condition>Stage IIC Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I (sargramostim and sentinel lymph node biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (hypertonic saline and sentinel lymph node biopsy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (sargramostim and sentinel lymph node biopsy)</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
    <description>Undergo sentinel lymph node biopsy</description>
    <arm_group_label>Arm I (sargramostim and sentinel lymph node biopsy)</arm_group_label>
    <arm_group_label>Arm II (hypertonic saline and sentinel lymph node biopsy)</arm_group_label>
    <other_name>sentinel node biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (sargramostim and sentinel lymph node biopsy)</arm_group_label>
    <arm_group_label>Arm II (hypertonic saline and sentinel lymph node biopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypertonic saline</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II (hypertonic saline and sentinel lymph node biopsy)</arm_group_label>
    <other_name>HTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stage IB or II cutaneous melanoma

          -  Primaries on the torso, upper and lower extremities and head and neck region

          -  Skin biopsy performed at least 5 days and no longer than 10 weeks from the time of
             initial entry into the study

          -  Bilirubin &lt; 2.0 ng/dl

          -  Creatinine &lt; 3.0 ng/dl

          -  Able to understand the consent competent to sign

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Prior wide excision with diameter of the excision &gt; 3 cm

          -  Primary melanoma arises from the eye or mucus membranes

          -  Clinical evidence of regional, intransit ,or distant metastases

          -  Second invasive melanoma

          -  Prior surgical procedures that would alter the drainage patterns and would prevent us
             from identifying sentinel lymph nodes (SN)

          -  Patients with primary or secondary immunodeficiencies

          -  Pregnancy

          -  Known allergy to sargramostim (GM-CSF)

          -  History of cardiac disease, in particular, supraventricular tachycardia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Essner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

